SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MorphoSys AG (MOR)
An SI Board Since January 2000
Posts SubjectMarks Bans
421 15 0
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
246The royalty is disappointing, I realize this is a small part of Morphosys. My ighmm-11/27/2008
245Morphosys always gets milestones of approx 9 to 12 mio€ (12 to 15 mio USD) from Germanecki-11/26/2008
244Appreciate the link and clarification. Do you know if they did any studies in Ighmm-11/25/2008
243GHMM, Take a look at this: ncbi.nlm.nih.gov By Carton JM, Sauerwald T, HawleyPseudo Biologist-11/25/2008
242I posted this on the Centocor board too Are you sure this is the Morphosys compghmm-11/25/2008
241Centocor has started a P2 with a Morphosys-mAB! <b>A Study to Evaluate thGermanecki-11/25/2008
240Massachusetts Mutual Life Insurance Company buyed over 3% of Morphosys! <b&gGermanecki-11/25/2008
239Key US Patent Granted on Antibodies Against GM-CSF to Treat Inflammatory DisordeGermanecki-11/25/2008
238Antibody Shows Ability to Inhibit Disease in an Established RA Model MorphoSys Germanecki-11/13/2008
237Full Year Profit Guidance Increased - MorphoSys AG Reports Strong Results for thGermanecki-10/30/2008
236Shionogi Extends Research Partnership with MorphoSys 09/29/2008 at 07:30 AM MGermanecki-9/29/2008
235MorphoSys Nominates First Pre-Development Program in Antibody Collaboration 09/2Germanecki-9/25/2008
234e2v to Establish Next Generation Biosensor System Using AbD Serotec-generated HuGermanecki-9/25/2008
233Revenues up 16 %, Operating Profit More Than Doubled <b>MorphoSys AG RepoGermanecki-7/29/2008
232MorphoSys Licenses RapMAT Technology to Astellas Wednesday July 23, 1:55 am ET scaram(o)uche-7/23/2008
231First AbD Serotec generated HuCAL Antibodies Distributed as Part of Clinical DiaGermanecki-7/17/2008
230MorphoSys and Integrated BioTherapeutics Provide Update Regarding USAMRIID BiodeGermanecki-7/17/2008
229Boehringer Ingelheim Gains Access to Additional MorphoSys Technology MARTINSRIEGermanecki-7/10/2008
228OncoMed Pharmaceuticals Extends License Agreement for Use of MorphoSys's CorGermanecki-6/18/2008
227Schering-Plough Extends Antibody Alliance with MorphoSys 19 May 2008 ThiGermanecki-5/20/2008
226Revenues up 16 %, Operating Profit Tripled MorphoSys AG Reports First Quarter 2Germanecki-4/29/2008
225MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 ProgrGermanecki-4/28/2008
224MorphoSys and the Leibniz-Institut für Molekulare Pharmakologie Sign Broad Germanecki-4/25/2008
223Invitation to Q1 2008 Conference Call of MorphoSys AG On April 29, 2008 MARTINSRGermanecki-4/23/2008
222DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Germanecki-3/27/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News